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Abstract 
The norovirus P particle, a subviral particle (~20 nanometers in diameter) formed by 24 protrusion (P) domains of the 
norovirus capsid protein, is easily made, stable, and highly immunogenic and thus an excellent vaccine candidate 
against noroviruses. Each P domain has three surface loops that have been shown useful for antigen presentation. We 
have successfully inserted a number of small (5 aa) to large (238 aa) antigens into these loops without affecting P 
particle formation and production. Increased immune responses were demonstrated by improved antibody titers 
induced by the P particle presented antigens compared to free antigens. Significantly increased neutralization of virus 
and/or protection against influenza virus and rotavirus challenges have also been demonstrated in mice after 
immunization with chimeric P particle vaccines containing flu M2e and rotavirus VP8 antigens, compared to free 
M2e and VP8 antigens, respectively. The chimeric P particle-induced antibodies also blocked binding of norovirus-
like particles (VLPs) to histo-blood group antigen (HBGA) receptors, indicating a potential dual vaccine against 
norovirus in addition to rotavirus and influenza virus. Taken together, the P particle appears to be an excellent 
platform for antigen presentation for vaccine development. The multiple surface loops and the large capacity of 
foreign antigen insertion suggest that this platform may have a wide application in vaccine development against 
different infectious diseases. 
 
Key words: norovirus; calicivirus; P particle; vaccine platform; antigen presentation; rotavirus vaccine; influenza virus vaccine. 
1. Introduction 
Biomaterials and bioengineering have become important areas of modern medicine. Because of their 
versatility and propensity to form arrays, viral and subviral particles are excellent substrates to construct 
presentation systems. These viral particles can be used as a platform for integration of foreign antigens in 
designed patterns through genetic engineering, which, in turn, can be developed into vaccines [1-8]. 
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Examples of successful insertions of antigens into viral particles have been described for several virus 
particles, including flock house virus (FHV)-like particle (VLP) containing a Bacillus anthracis antigen 
[9], hepatitis B virus (HBV) capsid-like particle (CLP) holding a surface antigen (OspA) of Borrelia 
burgdorferi  [10-12], and the cowpea mosaic virus (CPMV) presenting a number of different antigens 
[13-20], although limitations have also been described in these presentation systems. In this study we 
assessed the usefulness of the norovirus P particle, a novel subviral particle of norovirus [21-23], as a 
multifunctional platform for vaccine development against different infectious diseases. 
1.1. Norovirus P particle  
Noroviruses are a group of non-enveloped RNA viruses within the family Caliciviridae causing 
epidemics of acute gastroenteritis in humans. The viruses are encapsulated by a protein capsid that is 
constituted by a single major structural protein, the capsid protein VP1. The capsid protein is divided into 
a shell (S) and a protruding (P) domain that constitute the interior shell and the exterior protrusions of the 
viral capsid [24]. These two domains, linked by a short hinge, can be structurally and functionally 
independent. When expressed in vitro, the S domain alone forms a smaller particle with smooth surface, 
the S particle [25, 26], whereas the P domain can form three different complexes, the P dimer [26-28], the 
P particle [21, 22, 29] and the small P particles [30]. Since all these P complexes are formed by the 
surface portion of a norovirus capsid and contain all elements required for interaction with carbohydrate 
receptors, they have been extensively used as models in studies of norovirus-host interaction [21, 22, 26, 
29, 31-33]. 
1.2. The hypothesis: the P particle may be an excellent platform for antigen presentation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 1. The principle of antigen presentation by a norovirus P particle. (A), the structure of the wild type P particle; (B), crystal 
structure of a protrusion of the P particle with indications of 3 surface loops of each P domain that may be excellent sites for antigen 
presentation; (C) and (D), when an epitope is inserted into loop 2 (C), 24 copies of the epitope will be presented on the surface of 
the chimeric P particle (D). 
 
The P particles (~840 kDa, ~20 nm in diameter) are easily produced in E. coli and yeast, are stable and 
highly immunogenic [34], and thus are an excellent vaccine candidate for human noroviruses [21, 35]. 
Structural analysis of the P particle by electron cryo-microscopy (cryo-EM) revealed an octahedral 
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symmetry (Fig 1A) consisting of 24 copies of P domains that organize into 12 P dimers [34, 36]. Further 
study of the P dimer by crystallography indicated three surface loops on the distal end of each P domain 
[28], corresponding to the outermost surface of the P particle (Fig 1A and B). These loops now have been 
shown to be excellent sites for foreign antigen insertion and presentation [23]. Since each P particle 
contains 24 P monomers and each P monomer has three surface loops, insertion of a single antigen into 
these loops will produce 24-72 copies of the antigen on the surface of a P particle. By this mean the 
immunogenicity of the inserted antigens may be significantly increased. Therefore, the P particle may 
serve as an effective vaccne platform for antigen presentation (Fig 1). 
2. Evidence to support the hypothesis 
To assess the usefulness of the P particle as a vaccine platform, a number of experiments have been 
performed to evaluate the capability and capacity of foreign antigen insertions, the production and 
stability of the chimeric P particle, the immune response and protection of the chimeric P particles when 
used as a vaccine, as well as the immunogenicity of the P particle backbone. The results that support the 
hypothesis are described below.  
2.1. Small peptide epitopes can be well presented by the P particles  
Our experiments started with insertions of seven small peptide epitopes. These included two cysteine-
containing peptides, a CNGRC (ligand of aminopeptidase N or CD13) [37] and a CDCRGDCFC (ligand 
of intergrins Įvȕ3) [38], a 7xhistidine tract (His tag, 7 aa), the T cell epitope of murine cytomegalovirus 
(YPHFMPTNL, 9 aa), the Epi8 epitope of Pseudomonas (NATAEGRAINRRVE, 14 aa) [39], the CD4+ T 
cell epitope of murine rotavirus VP6 (RLSFQLMRPPNMTP, 14aa) [40], and the M2 extracellular epitope 
(M2e) of influenza virus (SLLTEVETPIRNEWGCRCNDSSD, 23 aa) (Table 1). These small epitopes 
were inserted into loop 2 of the P domain (Fig 1) and the chimeric P proteins were expressed using the 
GST Gene Fusion System (GE Healthcare) [35]. The results showed that insertion of all these short 
peptide into loop 2 individually did not affect the production of the chimeric P proteins in E. coli. The P 
particle formation was demonstrated by a defined major peak at ~840 kDa in a gel filtration analysis [35]. 
The exposure of the inserted epitopes was detected by binding of the chimeric P particle to the Talon resin 
(His tag) or to antigen-specific antibodies by EIAs. 
2.2. Large protein antigens can also be presented by the P particle platform  
To examine the capacity of the loops for foreign antigen insertion, we chose the core proteins (159 aa) 
of rotavirus spike protein VP8 of two serotypes, Wa (G1P8) and DS1 (G2P4), and the green fluorescence 
protein (GFP, 238 aa) to determine if the P particle can handle larger antigens (Table 1). These three 
proteins were inserted into loop 2 of the P domain through a cloning cassette containing two restriction 
enzyme sites (SpeI/ClaI) [35]. The chimeric P proteins were generated using the same approach described 
above. In all cases, the chimeric P proteins were expressed well and formed chimeric P particles. The 
particle formation of the P-VP8 chimeric protein has also been confirmed by cryo electron microscopy. 
The presentation of the VP8 on the surface of the particle was further demonstrated by fitting of the 
crystal structure of the VP8 into the density map of the extended protrusion of the chimeric P particle 
[35]. Successful insertion of the GFP in the chimeric P particle was shown by the size of the chimeric 
protein on a SDS PAGE, the defined particle peak in gel filtration and the emission of green fluorescence 
of the chimeric P particle. This data indicated that the P particle platform has a capacity of antigen 
insertion of at least 238 amino acids. 
2.3. All three loops of the P particle are capable of presenting foreign antigens 
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Table 1. A list of small to large antigens that have been inserted into the surface loops of the norovirus P particles 
and their immune responses in mice. 
 
 
 
Inserted antigens 
 
size 
(aa) 
 
Inserted 
location 
 
Particle 
formation 
 
Yield in soluble 
protein  
(mg/liter culture) 
 
Increased 
antibody 
response 1  
 
Increased 
neutralizing 
titer 1 
 
Increased 
protection 1 
CNGRC (ligand of cd13) 5 Loop 2 yes ~7 / / / 
CDCRGDCFC (ligand of intergrins) 9 Loop 2 yes ~7 / / / 
7xHistidine  7 Loop 1 yes ~5 yes / / 
7xHistidine  7 Loop 2 yes ~5 yes / / 
7xHistidine  7 Loop 3 yes ~5 yes / / 
T cell epitope of murine CMV 9 Loop 2 yes ~3 / / / 
Epi8 epitope of Pseudomonas 14 Loop 2 yes ~3 / / / 
T cell epitope of murine RV VP6 14 Loop 1 yes ~3 / / / 
T cell epitope of murine RV VP6 14 Loop 2 yes ~3 / / / 
M2e epitope of influenza virus 23 Loop 2 yes ~5 yes / yes 
Human RV VP8 (Wa, G1P8) 159  Loop 1 yes <0.1 / / / 
Human RV VP8 (Wa, G1P8) 159  Loop 2 yes ~15 yes yes / 
Human RV VP8 (Wa, G1P8) 159  Loop 3 yes ~5 / / / 
Human RV VP8 (DS1, G2P4) 159 Loop 2 yes ~10 yes yes / 
Murine RV VP8 (EDIM) 159 Loop 2 yes ~2 yes / yes 
Green fluorescence protein (GFP) 238 Loop 1 yes ~1 / / / 
Green fluorescence protein (GFP) 238 Loop 2 yes ~1 / / / 
Green fluorescence protein (GFP) 238 Loop 3 yes ~1 / / / 
 
1 For detailed data of these measurements please refer to reference [35]; / indicates that the measurement has not yet 
been performed.
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We then examined whether the other two surface loops (loops 1 and 3) are also capable of presenting 
foreign antigens. Two small epitopes (His tag and the T cell epitope of murine rotavirus VP6) and two 
large protein antigens (VP8 of human rotavirus and GFP) were tested (Table 1). Most of these insertions 
did not affect the production of the chimeric P proteins. Gel filtration followed by Talon resin binding and 
antigen detection EIA confirmed the P particle formation and the exposure of the His tag and the other 
inserted antigens. The only failure that occurred was the insertion of VP8 into loop 1. This insertion 
resulted in a low yield (<0.1 mg/liter bacterial culture) of the chimeric protein, possibly because of an 
instability of the resulting chimeric P protein (Table 1). These data indicated that all of the three loops are 
useful in presenting an antigen, although loop 1 may be more selective for certain antigens. 
2.4. The P particle presented small and large antigens induced enhanced immune responses  
The chimeric P particles containing small peptides, His tag or M2e, induced significantly higher 
antibody responses in mice against the inserted peptides than that induced by the free peptides alone and 
by the P dimer presented His tag after an intranasal immunization without adjuvant [35]. Similarly, the 
chimeric P particles containing rotavirus VP8s resulted in significantly higher antibody responses in mice 
than that induced by the free VP8s for both types [8] (Wa) and [4] (DS1). The antisera induced by the P 
particles-VP8 chimera also revealed significantly higher neutralizing titers against rotavirus than the 
antisera induced by the free VP8 [35]. These data indicated that the P particles are a useful platform for 
immune enhancement of antigens. 
2.5. The chimeric P particles protected mice from virus infection 
Two chimeric P particles containing either the influenza virus M2e or the murine rotavirus VP8 were 
studied. The P particle-M2e chimera was delivered intranasally without an adjuvant or subcutaneously 
with Montanide ISA 720 adjuvant (Sepic, France). Mice were fully protected (100% survived) against the 
lethal challenge of an mouse adapted human influenza virus PR8 (H1N1), while very low survival rates 
(<10%) were found in control mice immunized with free M2e peptide, wild type P particle, or phosphate 
buffer saline (PBS), respectively.  
 
The chimeric P particle containing murine rotavirus (EDIM) VP8 was also delivered intranasally to 
mice. Mice were then challenged with EDIM and the quantity of viral shedding in the stool was 
determined by ELISA. When compared to control mice that were immunized by PBS, wild type P particle 
and free EDIM VP8, respectively, the group that received the chimeric P particle containing EDIM VP8 
shed the lowest amount of rotavirus [35]. These data further demonstrated that the P particles can be used 
as a platform for vaccine development and both the P particle-M2e and -VP8 chimeras are promising 
vaccine candidates against influenza virus and rotavirus. 
2.6. The chimeric P particles induced antibody against norovirus that block binding of norovirus to viral 
receptors 
In addition to producing antibodies against influenza virus and rotavirus, the chimeric P particle-M2e 
and -VP8 also induced high antibody titers against norovirus in mice. The mouse sera were able to block 
the binding of norovirus VLPs to histo-blood group antigens (HBGAs), the host receptors of human 
noroviruses [41-43], in both saliva- and synthetic oligosaccharide-based binding assays [21, 35, 44, 45]. 
These results suggest that the chimeric P particles can be used as dual vaccines against norovirus in 
addition to rotavirus and influenza virus, respectively.  
3. Conclusions 
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In this study we have provided solid evidence on the usefulness of the norovirus P particle as a novel 
platform for antigen presentation for immune enhancement. Significantly increased immune responses 
and protection were observed for both small and large antigens that are presented by the P particles. The 
two chimeric P particles created in this study, the P particle-M2e and the P particle-VP8, are promising 
vaccine candidates against influenza virus, rotavirus and norovirus and further development of these 
chimeric P particles into a useful vaccine is warranted. Further studies to explore diverse applications of 
the platform for other antigens by taking advantage of all three surface loops and the large capacity of the 
loops for foreign antigen insertion also are necessary.  
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